Actinogen Medical ACW.AX · AUD

Its shares trade on ASX under the ticker ACW.AX. It has been listed since 16 October 2007. In the fiscal year to 30 June 2025, it reported revenue of A$5.5m and a net loss of A$14.7m. At that date it held total assets of A$24.5m and shareholders' equity of A$18.3m.

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. The company has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The firm conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Geoffrey BrookeNon-Executive Chairman of the Board, since 2017A$239,816
• Dr. Steven GourlayChief Executive Officer, Managing Director, Executive Director, since 2021A$955,166
• Mr. William SouterChief Financial Officer
• Ms. Cheryl TownsendVice President of Clinical Operations
• Mr. Michael RobertsHead of Investor Relations and Comms
• Dr. Dana HiltChief Medical Officer
• Ms. Fujun LiHead of Manufacturing
• Mr. Andrew UdellChief Commercial Officer
• Mr. Peter WebseCompany Secretary
• Mr. Malcolm MccomasNon-Executive DirectorA$122,695
• Mr. George MorstynNon-Executive DirectorA$115,646
• Dr. Nicki VasquezNon-Executive Independent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.